National Harbor, Md.—Rounding down doses for injectable monoclonal antibodies within 10% to achieve more efficient use of vial sizes could lead to substantial savings for health plans, according to a study from Magellan Rx Management, the pharmacy benefit management division of Magellan Health Inc.
Sam Leo, PharmD
The company’s review of prior authorization requests for bevacizumab (Avastin, Genentech), infliximab (Remicade, Janssen) and rituximab (Rituxan, Genentech/Biogen) among